What Is Nangibotide? Definition and What Research Reports

Definition

Nangibotide is an investigational synthetic peptide that has been studied as an inhibitor of the triggering receptor expressed on myeloid cells-1 (TREM-1), a receptor that amplifies inflammatory signalling in innate immune cells such as neutrophils and monocytes. In the published literature it is described as a short peptide sequence derived from TREM-like transcript-1 (TLT-1), a natural ligand-related protein, and it has been administered as a continuous intravenous infusion in clinical studies rather than by any other route. Its first description in humans was a safety and pharmacokinetics study framed around modulation of the innate immune response through TREM-1 receptor inhibition (PMID 29885068). The term is used in research as the name of a specific drug candidate, not as a category of compounds.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, illness or treatment.

What Class of Molecule Is It?

Nangibotide belongs to the broad class of peptide therapeutics — short chains of amino acids manufactured synthetically. Within that class it is usually grouped with immune-modulating peptides, because its described mechanism is receptor-level interference rather than antibiotic, antiviral or hormonal activity.

• Molecule type: synthetic peptide.
• Described target: the TREM-1 receptor pathway on innate immune cells.
• Described origin: a sequence related to TREM-like transcript-1 (TLT-1).
• Route used in studies: intravenous infusion in hospital settings (PMID 32468087).
• Status: investigational; it is not an approved drug in the United States or the European Union.

How the Term Is Used in Research

In peptide and critical-care literature, "nangibotide" appears almost exclusively as the name of the study drug in trials of TREM-1 inhibition. Papers that use the word typically fall into one of four groups: first-in-human pharmacology, septic shock trials, a COVID-19 trial, and preclinical animal work outside critical care. A closely related term that appears alongside it is sTREM-1 (soluble TREM-1), a circulating biomarker used in these programmes to identify patients with higher TREM-1 pathway activation; the phase 2b programme was explicitly designed around testing a biomarker enrichment strategy (PMID 37269870).

What the Published Literature Reports

First-in-human pharmacology

The earliest human publication was a first-in-man safety and pharmacokinetics study, in which researchers characterised how nangibotide behaved after administration and reported on its tolerability as a new modulator of the innate immune response through TREM-1 receptor inhibition (PMID 29885068). That work established the pharmacological basis for moving the peptide into critical-care populations rather than demonstrating any clinical benefit.

Septic shock

The first patient study was a phase 2a randomised controlled clinical trial in septic shock, where the study assessed nangibotide against placebo in an intensive-care population (PMID 32468087). A protocol paper then described the design and rationale of ASTONISH, a phase IIb randomised controlled trial set up to test efficacy, safety and tolerability in the same population (PMID 34233965). ASTONISH results were subsequently published as a double-blind, randomised, controlled phase 2b trial that prospectively evaluated efficacy, safety and the optimal soluble TREM-1 biomarker enrichment strategy; researchers reported that the trial did not establish a definitive benefit across the studied population and instead framed its findings around which biomarker-defined subgroups warranted further investigation (PMID 37269870).

COVID-19

The ESSENTIAL trial was a randomised, double-blind study that evaluated the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 who were receiving respiratory support (PMID 37350989). As with the septic shock programme, the study was designed around the hypothesis that dampening TREM-1 signalling might reduce organ dysfunction driven by an exaggerated innate immune response, and results were reported in relation to baseline biomarker status rather than as a general treatment effect (PMID 37350989).

Preclinical work outside critical care

Outside acute care, one animal study reported that nangibotide attenuated osteoarthritis by inhibiting osteoblast apoptosis and reducing TGF-β activity in subchondral bone, positioning TREM-1 as a target in joint pathology (PMID 35391646). Findings from an animal model of this type are not evidence of an effect in humans, and no human osteoarthritis trial of nangibotide appears in the verified literature summarised here.

Safety and Adverse Events: What Studies Report

Safety was a stated objective of every human publication on this peptide. The first-in-man study was explicitly designed as a safety and pharmacokinetics evaluation (PMID 29885068), and the phase 2a septic shock trial evaluated safety alongside exploratory efficacy measures in critically ill patients (PMID 32468087). The ASTONISH protocol listed safety and tolerability among its formal endpoints (PMID 34233965), and the published phase 2b results reported on safety as well as efficacy and biomarker enrichment (PMID 37269870). The COVID-19 trial likewise reported both efficacy and safety outcomes in patients receiving respiratory support (PMID 37350989). Because all of this work was conducted in monitored hospital environments — healthy-volunteer units and intensive care units — the adverse-event profile described in these papers cannot be extrapolated to any unsupervised setting.

Regulatory and Availability Status

Nangibotide has not been approved by any major regulator as a medicine. Its human data consist of early-phase trials, and phase 2 studies of this kind are designed to explore dose, biomarker strategy and safety signals rather than to support marketing authorisation. Any material sold under this name outside a clinical trial is not an approved pharmaceutical product. This page is descriptive of the published record only and does not constitute legal, regulatory or medical advice.

Common Points of Confusion

• Nangibotide is not an antibiotic. In the septic shock trials it was studied as an addition to standard care, not as an anti-infective agent (PMID 32468087).
• TREM-1 and sTREM-1 are different things. TREM-1 is the receptor described as the drug target; soluble TREM-1 is the circulating biomarker used to define enrichment strategies in the phase 2b programme (PMID 37269870).
• The osteoarthritis finding is preclinical. It was reported in an animal model of joint disease, not in patients (PMID 35391646).
• It is an infusion drug in studies. Every human study cited here delivered it intravenously in a hospital setting (PMID 34233965).

References

• A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition (British Journal of Clinical Pharmacology, 2018)
• Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial (Intensive Care Medicine, 2020)
• Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial (BMJ Open, 2021)
• Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone (Inflammopharmacology, 2022)
• Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial (The Lancet Respiratory Medicine, 2023)
• Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial (EClinicalMedicine, 2023)